Edward F. Patz Jr., MD

Professor of Radiology
Professor in Pathology
Professor in Pharmacology & Cancer Biology

Department / Division
Radiology / Chest Radiology

Address:
DUMC 3808
Durham, NC 27710

Appointment Telephone:
919-684-2711

Office Telephone:
919-684-7311

Fax:
919-684-7168

Training:

• MD, University of Maryland School of Medicine, 1985

Residency:

• Radiology, Brigham and Women's Hospital (Massachusetts), 1985-1990

Fellowship:

• Thoracic Imaging, Brigham and Women's Hospital (Massachusetts), 1989-1990

Clinical Interests:
General thoracic imaging, PET imaging of the thorax, interventional procedures in the thorax, biomarkers, early detection of cancer

Research Interests:

There are numerous ongoing clinical studies primarily focused on the early detection of lung cancer.

The basic science investigations in our laboratory concentration on three fundamental translational areas,

1) Development of molecular imaging probes - We use several different approaches, including phage display, and in collaboration with our colleagues in the Chemistry Department, a mass spectrometry based method. These efforts are to develop novel imaging probes that characterize and phenotype tumors.

2) Discovery of novel lung cancer biomarkers - We explored the use of proteomics, autoantibodies, and genomics to discover blood and tissue biomarkers for early cancer detection and phenotyping of lung cancer.

3) Host response to cancer - We study the native immune response to tumors as this may provide cues to relevant diagnostic and therapeutic targets. Most recently we have focused on intratumoral lymphocytes and their specific tumor antigens.

Publications:

• Birchard, KR; Hoang, JK; Herndon, JE; Patz, EF. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009;115:581-586. Abstract
  
  
• Gottlin, EB; Xiangrong Guan, ; Pegram, C; Cannedy, A; Campa, MJ; Patz, EF. Isolation of novel EGFR-specific VHH domains. Journal of Biomolecular Screening. 2009;14:77-85. Abstract
  
  
• Berghmans, T; Dusart, M; Paesmans, M; Hossein-Foucher, C; Buvat, I; Castaigne, C; Scherpereel, A; Mascaux, C; Moreau, M; Roelandts, M; Alard, S; Meert, AP; Patz, EF; Lafitte, JJ; Sculier, JP; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology. 2008;3:6-12. Abstract
  
  
• Hoang, JK; Hoagland, LF; Coleman, RE; Coan, AD; Herndon, JE; Patz, EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. Journal of Clinical Oncology. 2008;26:1459-1464. Abstract
  
  
• Hopper, ED; Roulhac, PL; Campa, MJ; Patz, EF; Fitzgerald, MC. Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. Journal of the American Society for Mass Spectrometry. 2008;19:1303-1311. Abstract
  
  
• Schultz, EM; Sanders, GD; Trotter, PR; Patz, EF; Silvestri, GA; Owens, DK; Gould, MK. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax. 2008;63:335-341. Abstract
  
  
• Hoagland, LF; Campa, MJ; Gottlin, EB; Herndon, JE; Patz, EF. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007;110:2260-2268. Abstract
  
  
• Patz, EF; Campa, MJ; Gottlin, EB; Kusmartseva, I; Guan, XR; Herndon, JE. Panel of serum biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology. 2007;25:5578-5583. Abstract
  
  
• Patz, EF. Integration of biomarkers and imaging. Journal of Thoracic Oncology. 2006;1:78-80. Abstract
  
  
• Patz, EF. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. Journal of National Cancer Institute. 2006;98:724-725. Abstract
  
  
• Petersen, RP; Campa, MJ; Sperlazza, J; Conlon, D; Joshi, MB; Harpole, DH; Patz, EF. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107:2866-2872. Abstract
  
  
• Howard, BA; Furumai, R; Campa, MJ; Rabbani, ZN; Vujaskovic, Z; Wang, XF; Patz, EF. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Research. 2005;65:8853-8860. Abstract
  
  
• MacMahon, H; Austin, JH; Gamsu, G; Herold, CJ; Jett, JR; Naidich, DP; Patz, EF; Swensen, SJ; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005;237:395-400. Abstract
  
  
• Howard, BA; Zheng, Z; Campa, MJ; Wang, MZ; Sharma, A; Haura, E; Herndon, JE; Fitzgerald, MC; Bepler, G; Patz, EF. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004;46:313-323. Abstract
  
  
• Patz, EF; Swensen, SJ; Herndon, JE. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. Journal of Clinical Oncology. 2004;22:2202-2206. Abstract
  
  
• Suber, RL; Flanders, VL; Campa, MJ; Patz, EF. Accentuation of differentially expressed proteins using phage technology. Analytical Biochemistry. 2004;333:351-357. Abstract
  
  
• Wang, MZ; Shetty, JT; Howard, BA; Campa, MJ; Patz, EF; Fitzgerald, MC. Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. Analytical Chemistry. 2004;76:4343-4348. Abstract
  
  
• Campa, MJ; Wang, MZ; Howard, B; Fitzgerald, MC; Patz, EF. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Research. 2003;63:1652-1656. Abstract
  
  
• Campa, MJ; Serlin, SB; Patz, EF. Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. Academic Radiology. 2002;9:927-932. Abstract
  
  
• Grannis, FW. Potential conflict of interest in AJRCCM. American Journal of Respiratory and Critical Care Medicine. 2002;166:1608. Abstract
  
  
• Heyneman, LE; Patz, EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261-266. Abstract
  
  
• Marom, EM; Erasmus, JJ; Pass, HI; Patz, EF. The role of imaging in malignant pleural mesothelioma. Seminars in Oncology. 2002;29:26-35. Abstract
  
  
• Marom, EM; Sarvis, S; Herndon, JE; Patz, EF. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223:453-459. Abstract
  
  
• Aloia, T; Bepler, G; Harpole, D; Goodman, PC; McAdams, HP; Erasmus, JJ; Herndon, JE; Patz, EF. Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. Cancer Epidemiology: the international journal of cancer epidemiology, detection and prevention. 2001;25:336-343. Abstract
  
  
• Crotty, E; Patz, EF. FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. Journal of Thoracic Imaging. 2001;16:89-93. Abstract
  
  
• Dammas, S; Patz, EF; Goodman, PC. Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer. 2001;33:11-16. Abstract
  
  
• Heyneman, LE; Herndon, JE; Goodman, PC; Patz, EF. Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. Cancer. 2001;92:3051-3055. Abstract
  
  
• Marom, EM; Aloia, TA; Moore, MB; Hara, M; Herndon, JE; Harpole, DH; Goodman, PC; Patz, EF. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99-107. Abstract
  
  
• Patz, EF; Black, WC; Goodman, PC. CT screening for lung cancer: not ready for routine practice. Radiology. 2001;221:587-591. Abstract
  
  
• Patz, EF; Goodman, PC. Low-dose spiral computed tomography screening for lung cancer: not ready for prime time. American Journal of Respiratory and Critical Care Medicine. 2001;163:813-814. Abstract
  
  
• Patz, EF; Goodman, PC; Bepler, G. Screening for lung cancer. New England Journal of Medicine. 2000;343:1627-1633. Abstract
  
  
• Patz, EF; McAdams, HP; Erasmus, JJ; Goodman, PC; Culhane, DK; Gilkeson, RC; Herndon, J. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998;113:1305-1311. Abstract
  
  
• Campa, MJ; Schreiber, G; Bepler, G; Bishop, MJ; McNutt, RW; Chang, KJ; Patz, EF. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Research. 1996;56:1695-1701. Abstract